Skip to main content
OpenTrials
Recruiting

NCT Number: NCT05836610

Hydrocortisone Therapy Optimization During Hypothermia Treatment in Asphyxiated Neonates

This is a prospective, single center, pharmacokinetic study of intravenous hydrocortisone therapy for systemic low blood pressure during hypothermia treatment in asphyxiated newborns. Patients will be allocated to hydrocortisone supplementation while receiving conventional inotropic therapy as needed.

The hypothesis is that a detailed study of hydrocortisone pharmacokinetics during therapeutic hypothermia would help to personalize steroid supplementation in asphyxiated neonates. As the overall metabolic rate decreases with lower body temperature, drug metabolism is likely to be reduced as well, and lower doses, or less frequent dosing will be sufficient to achieve the targeted steroid range and biological effects in asphyxiated neonates with relative adrenal insufficiency. Thus, the investigators are planning to measure initial, baseline serum cortisol levels and serial serum cortisol levels after hydrocortisone supplementation in cooled asphyxiated neonates.

Recruiting

Interested in participating?

Request Info

Key information

Age range

Up to 72 hour

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Semmelweis University Department of Pediatrics (Bókay street Unit)

Budapest, Pest County, 1083, Hungary

Location status: Recruiting

Location contact

Ollé Viktória

CONTACT

[email protected]

About this study

The ultimate goal of the present study, is to describe a new approach of more personalized and safe care to infants with birth asphyxia and hemodynamic instability.

Asphyxiated infants often present with multiorgan failure and low blood pressure. Therapeutic hypothermia, the standard of care, could worsen hemodynamic instability; therefore, treatment of cardiovascular impairment represents a major challenge in this clinical setting. An association was previously described between hypotension and low serum cortisol values in this patient population, and it was suggested that relative adrenal insufficiency (RAI) is an important factor in the circulatory compromise of these patients. In the "CORTISoL" clinical trial, it was also demonstrated that low-dose hydrocortisone therapy was effective in the treatment of cardiovascular impairment in asphyxiated neonates; however, some gaps remain in the knowledge on optimal dosing. Importantly, steroid therapy should be administered at the lowest effective dose and for the shortest possible duration in this vulnerable population.

In the current pharmacokinetic study, the investigators propose a stepwise approach to more detailed understanding of RAI and hydrocortisone pharmacokinetics in asphyxiated neonates. The findings would certainly aid clinical decision-making and allow for more personalized therapeutic interventions for the treatment of hemodynamic instability.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • gestational age ≥ 36 weeks
  • provision of whole-body hypothermia treatment (as described by Azzopardi et al.)
  • presence of systemic hypotension (defined as a mean arterial pressure less than the gestational age in weeks)
  • indication for hydrocortisone treatment during hypothermia by the attending physician
  • indwelling arterial catheter to take blood samples without additional painful punctures: umbilical arterial catheter or peripheral arterial catheter
  • written informed parental consent

Exclusion criteria

  • infants who are expected to be > 6 hours of age (not suitable for cooling)
  • critical congenital abnormalities
  • genetic disease
  • signed informed consent is unavailable

Treatment and study plan

Hydrocortisone

Drug

intravenous bolus hydrocortisone therapy during hypothermia treatment

Other names: Solu-Cortef

Primary outcomes

  1. Mean blood pressure increase

    Time frame: 2 hours

    5 mmHg increase in mean arterial blood pressure after drug administration

Secondary outcomes

  1. Cardiovascular management

    Time frame: 72 hours

    Length, cumulative and peak dose of inotrope treatment

  2. Presence of relative adrenal insufficiency at baseline

    Time frame: Before hydrocortisone administration within max. 72 hours

    Low serum cortisol level at baseline

  3. MRI outcome

    Time frame: 4-10 days

    Brain injury on MRI examinations

  4. Long term neurodevelopmental outcome

    Time frame: 18-42 month

    Performance on motor and mental scales of Bayley III scales of infant development

Other outcomes

  1. Multiorgan failure

    Time frame: 72 hours

    Presence of multiorgan failure during hypothermia

Study contacts

Contact information is provided by the study sponsor or research team.

Dobi Marianna, MD

CONTACT

[email protected]

+36303357529

Kata Kovacs, MD, PhD

CONTACT

[email protected]

+36204969653

Sponsors and collaborators

Lead sponsor

Semmelweis University

Other

Registry information

Official study title

Hydrocortisone Therapy Optimization During Hypothermia Treatment in Asphyxiated Neonates - a Pharmacokinetic Study

Acronym: UniCort

Important dates

Study start
2021
Primary completion
2027
Study completion
2027
First posted
May 1, 2023
Registry last updated
Apr 28, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.